NAD+: cellular energy, DNA repair, and the longevity molecule — 2026 evidence-based guide

If you follow longevity science at any depth, you have encountered NAD+. It is arguably the single most commercially successful molecule in the anti-aging supplement market — a billion-dollar industry built on a straightforward proposition: NAD+ levels fall as you age, low NAD+ correlates with cellular dysfunction, therefore raising NAD+ should reverse or slow aging. The logic sounds airtight. The evidence base is more complicated than the marketing suggests.

NAD+ is not a peptide in the traditional sense — it is a dinucleotide coenzyme. But it sits at the center of the same longevity and cellular optimization conversation that drives interest in mitochondrial peptides like SS-31 and MOTS-C, and it interacts with many of the same biological pathways. Understanding NAD+ is foundational to understanding modern longevity biology.

This guide covers the biochemistry without oversimplifying it, the human trial data without cherry-picking it, and the practical supplementation landscape without selling it. NAD+ is a genuinely important molecule. That does not automatically make NAD+ supplementation a genuinely effective intervention.

What is NAD+?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every cell of every living organism. It exists in two forms: NAD+ (oxidized, the electron acceptor) and NADH (reduced, the electron carrier). The ratio between these two forms is critical for cellular metabolism — it determines the rate of mitochondrial energy production, the activity of DNA repair enzymes, and the function of a family of regulatory proteins called sirtuins that influence gene expression, inflammation, and stress resistance.

NAD+ participates in over 500 enzymatic reactions, making it one of the most versatile molecules in human biochemistry. Its three primary functional domains are energy metabolism (shuttling electrons in the mitochondrial electron transport chain to produce ATP), DNA maintenance (serving as the essential substrate for PARP enzymes that repair DNA strand breaks), and cellular signaling (activating sirtuins that regulate inflammatory pathways, circadian rhythm, and metabolic gene expression).

Your body both synthesizes NAD+ from dietary precursors (tryptophan, niacin, NR, NMN) and recycles it continuously through salvage pathways. The salvage pathway — converting nicotinamide back to NMN and then to NAD+ via the enzyme NAMPT — accounts for the majority of daily NAD+ turnover. When this recycling machinery slows with age, NAD+ levels fall. Understanding this recycling bottleneck is key to understanding why precursor supplementation has become the dominant strategy for NAD+ restoration.

Why does NAD+ decline with age?

The age-related decline in NAD+ is well-documented across multiple tissues and measurement methodologies. Human studies measuring NAD+ in blood, skin, and brain tissue consistently show a decline of approximately 50% between ages 40 and 60, with continued erosion thereafter. Four primary mechanisms drive this decline:

• CD38 upregulation — CD38 is a membrane enzyme that consumes NAD+ as a substrate. Its expression increases substantially with age and chronic inflammation. CD38 is now considered the largest single contributor to age-related NAD+ depletion, consuming far more NAD+ than sirtuins or PARPs combined. Research from Eduardo Chini's laboratory at Mayo Clinic has demonstrated that CD38 knockout mice maintain youthful NAD+ levels into old age
• Chronic PARP activation — As DNA damage accumulates with age, PARP1 and PARP2 enzymes activate more frequently to repair strand breaks. Each repair event consumes one molecule of NAD+. In conditions of high oxidative stress or genomic instability, PARP hyperactivation can deplete NAD+ pools faster than salvage pathways can replenish them
• NAMPT decline — Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway, decreases in expression and activity with age. This slows the recycling of nicotinamide back to NAD+, creating a supply-side constraint on NAD+ homeostasis
• Chronic inflammatory signaling — Senescent cells and chronic low-grade inflammation (sometimes called "inflammaging") upregulate CD38 expression on immune cells and drive increased PARP activity simultaneously, creating a dual drain on NAD+ pools

The important nuance: NAD+ decline is a downstream consequence of aging processes (accumulated DNA damage, chronic inflammation, cellular senescence). It is not necessarily a root cause. This distinction matters enormously for the supplementation question — if low NAD+ is a symptom rather than a driver, then artificially raising levels may not address the underlying biology.

The three critical NAD+-dependent pathways

Sirtuins: the longevity regulators

Sirtuins (SIRT1 through SIRT7) are a family of NAD+-dependent deacetylase enzymes that remove acetyl groups from proteins, modifying their function. They regulate gene expression patterns associated with stress resistance, DNA repair, inflammation suppression, mitochondrial biogenesis, and circadian rhythm maintenance. SIRT1 and SIRT3 have received the most attention in longevity research — SIRT1 operates primarily in the nucleus and cytoplasm to regulate metabolic gene expression, while SIRT3 works inside mitochondria to optimize oxidative phosphorylation and reduce reactive oxygen species production.

The critical dependency: sirtuins cannot function without NAD+ as a cofactor. When NAD+ levels fall, sirtuin activity falls proportionally. David Sinclair's foundational hypothesis is that restoring NAD+ levels restores sirtuin activity, which in turn restores youthful gene expression patterns. In mice, this logic has produced genuinely remarkable results — aged mice treated with NAD+ precursors show improved mitochondrial function, enhanced insulin sensitivity, increased exercise endurance, and gene expression profiles that resemble younger animals.

PARPs: the DNA repair machinery

Poly(ADP-ribose) polymerases (PARPs) are enzymes that detect and initiate repair of DNA strand breaks. PARP1 is the most active, responsible for repairing the estimated 10,000-100,000 DNA lesions that occur in every cell every day from normal metabolic processes, UV exposure, and environmental toxins. Each repair event consumes NAD+ — PARP1 cleaves NAD+ to produce ADP-ribose polymers that signal recruitment of repair complexes to damage sites.

The tension between PARPs and sirtuins is biologically significant: both enzymes compete for the same limited NAD+ pool. In conditions of high DNA damage (aging, oxidative stress, genotoxin exposure), PARP hyperactivation can consume so much NAD+ that sirtuin activity is suppressed by substrate depletion. Some researchers have proposed that this PARP-sirtuin competition is a fundamental mechanism of aging — genomic instability drives PARP activity that starves sirtuins of the NAD+ they need to maintain protective gene expression patterns.

CD38: the NAD+ consumer

CD38 is a transmembrane glycoprotein expressed on immune cells and many other tissues. It uses NAD+ as a substrate to produce cyclic ADP-ribose, a calcium-signaling molecule. Unlike sirtuins and PARPs, which use NAD+ for clear cellular maintenance purposes, CD38's consumption of NAD+ appears partly wasteful — the calcium signals it generates are important for immune cell activation, but the sheer volume of NAD+ consumed by CD38 in aged tissues far exceeds what immune signaling requires.

Eduardo Chini's group at Mayo Clinic demonstrated that CD38 expression increases two-to-threefold with aging in multiple tissues, and that CD38 accounts for the majority of age-related NAD+ decline. Pharmacological CD38 inhibitors (like apigenin, found in parsley and celery) can partially restore NAD+ levels in aged mice without any precursor supplementation. This has led some researchers to argue that inhibiting CD38 may be a more mechanistically sound approach to restoring NAD+ than simply flooding the system with more precursors.

NAD+ precursors: NMN vs NR — which one works?

The supplement industry has coalesced around two primary NAD+ precursors: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are converted to NAD+ through distinct but overlapping metabolic pathways, and both have accumulated meaningful human pharmacokinetic data. The NMN-versus-NR debate generates outsized controversy online, but the clinical reality is that both reliably raise blood NAD+ levels.

The honest assessment: from the standpoint of NAD+ blood-level elevation, NMN and NR appear roughly equivalent when dose-adjusted. Neither has demonstrated superiority in clinical outcomes because neither has been tested in a large, long-term outcomes trial. The NMN-versus-NR debate is largely a marketing and intellectual-property dispute, not a scientific one.

IV NAD+ infusions: the clinical experience

IV NAD+ infusions (typically 250-1000 mg delivered over 2-4 hours) represent the most direct route of NAD+ administration, bypassing digestive absorption entirely and achieving plasma NAD+ levels impossible with oral precursors. They are widely offered at longevity clinics, addiction treatment centers, and concierge medicine practices at prices ranging from $250-$1,500 per session.

The infusion experience itself is notably unpleasant for most patients. Common side effects during infusion include chest tightness or pressure, nausea, abdominal cramping, flushing and warmth, headache, and anxiety. These effects are dose-rate dependent — slowing the infusion rate reduces symptoms but extends treatment duration. Most clinics titrate the drip rate to patient tolerance, which means a "500 mg infusion" might take anywhere from 90 minutes to 4 hours depending on individual sensitivity.

The scientific rationale for IV NAD+ over oral precursors is pharmacokinetically straightforward: you achieve higher peak NAD+ levels faster. What is not established is whether higher peak levels produce better biological outcomes than the sustained, moderate elevation achieved with daily oral precursors. No head-to-head trial has compared IV NAD+ infusions to oral NMN or NR for any clinical endpoint. The IV approach generates more dramatic subjective experiences (many patients report euphoria, mental clarity, and energy surges during or after infusion), but subjective experience is not a reliable proxy for biological benefit — placebo IV infusions also produce subjective responses.

What do human clinical trials actually show?

By 2026, the human trial landscape for NAD+ precursors has matured considerably beyond the early pharmacokinetic studies. Multiple randomized controlled trials have been published, primarily using NR (nicotinamide riboside, brand name Tru Niagen) and NMN. The consistent finding across nearly all trials is that oral precursors reliably raise blood NAD+ levels. The inconsistent finding is whether that biochemical change translates to clinical benefit.

Trials showing benefit

• NR and cardiovascular function — A 2018 crossover trial in healthy middle-aged and older adults (n=24) by Martens et al. at the University of Colorado found that NR supplementation (500 mg twice daily for 6 weeks) reduced systolic blood pressure by 3-4 mmHg and reduced aortic stiffness, suggesting vascular benefit
• NMN and muscle insulin sensitivity — A 2021 Washington University trial (n=25 postmenopausal women with prediabetes) by Yoshino et al. found that NMN (250 mg/day for 10 weeks) improved skeletal muscle insulin signaling and glucose uptake, though it did not improve other metabolic markers
• NMN and exercise performance — A 2022 trial in recreational runners (n=48) found that NMN supplementation (600 mg/day) improved aerobic capacity and ventilatory threshold compared to placebo over 6 weeks of training
• ALIVE study (NR) — The ALIVE trial demonstrated improvements in NAD+ metabolomics and certain markers of mitochondrial function in older adults receiving NR for 8 weeks, providing mechanistic support for precursor supplementation

Trials showing no benefit or mixed results

• NR and mitochondrial function in heart failure — A trial of NR in stable heart failure patients showed NAD+ elevation but no improvement in cardiac function, exercise capacity, or quality of life measures
• NR and kidney function — Studies in patients with acute kidney injury and chronic kidney disease showed NAD+ elevation without consistent clinical improvement
• NR and metabolic syndrome — A trial in obese men (n=40) found that NR (2000 mg/day for 12 weeks) raised NAD+ but did not improve insulin sensitivity, body composition, or energy metabolism markers
• NMN and body composition — Several NMN trials in overweight adults have failed to demonstrate significant changes in body weight, fat mass, or lean mass despite confirmed NAD+ elevation

The pattern emerging from this clinical evidence is consistent and sobering: NAD+ precursors reliably raise NAD+ levels (the biochemistry works), but raising NAD+ levels does not reliably improve clinical outcomes in humans (the medicine is uncertain). This does not mean NAD+ supplementation is useless — some trials show genuine benefit in specific populations and endpoints. But it means the sweeping anti-aging claims made by supplement companies are not supported by the current weight of human evidence.

David Sinclair and the NAD+ longevity hypothesis

No discussion of NAD+ is complete without addressing David Sinclair, the Harvard geneticist whose research and public advocacy have done more to popularize NAD+ supplementation than any other single figure. Sinclair's laboratory has published influential work demonstrating that NMN supplementation in aged mice reverses age-related vascular decline, restores muscle capillary density, improves mitochondrial function, enhances exercise endurance, and produces gene expression profiles resembling younger animals.

Sinclair's "Information Theory of Aging" positions NAD+ decline as a central node: falling NAD+ reduces sirtuin activity, which compromises the epigenetic maintenance systems that keep cells functioning in their differentiated, youthful state. Restoring NAD+ restores sirtuin activity, which in turn restores youthful gene expression. It is an intellectually elegant framework with substantial mouse data behind it.

The legitimate criticisms are worth acknowledging directly. Sinclair has significant financial interests in NAD+-related companies (he co-founded MetroBiotech, which develops NMN-based therapeutics, and has advised several supplement companies). His mouse results, while published in high-impact journals, have not always replicated cleanly in independent laboratories. And his public statements about NAD+ benefits often extrapolate from mouse data to human claims with less caution than the evidence warrants. None of this invalidates his research — but it does mean his enthusiasm should be weighed against the full clinical evidence base, not accepted as a substitute for it.

What has Huberman Lab said about NAD+?

Andrew Huberman has discussed NAD+ extensively across multiple podcast episodes, making it one of the most thoroughly covered longevity topics on Huberman Lab. His coverage has been more balanced than most popular sources, acknowledging both the compelling mechanistic rationale and the limitations of human evidence.

Huberman has covered the sirtuin-NAD+ connection in depth, explaining how NAD+ depletion affects cellular repair mechanisms and why restoring levels is mechanistically attractive. He has discussed the NMN-versus-NR landscape, generally noting that both raise NAD+ and that the scientific distinction between them is smaller than marketing suggests. He has addressed sublingual delivery of NMN as potentially superior to swallowed capsules for bioavailability, and has discussed the role of the Slc12a8 transporter in direct NMN uptake.

Notably, Huberman has also discussed CD38 inhibition (via apigenin and quercetin) as a complementary strategy to precursor supplementation — an approach that targets the consumption side of the NAD+ equation rather than just the supply side. He has been appropriately cautious about IV NAD+ claims, particularly regarding addiction treatment applications where controlled trial data is thin.

Where Huberman's coverage converges with our assessment: NAD+ is biologically important, precursors demonstrably raise levels, but the jump from "higher NAD+ levels" to "better health outcomes" in humans requires more evidence than currently exists. Where his coverage occasionally diverges: he has at times discussed personal supplementation practices that may imply more certainty about benefits than clinical data supports, though he typically qualifies these with appropriate disclaimers.

Safety and side effects

Oral NAD+ precursors (NMN and NR) have demonstrated a favorable safety profile across published human trials. NR in particular has been through multiple safety studies and received FDA Generally Recognized as Safe (GRAS) status. That said, several safety considerations deserve attention:

• Gastrointestinal effects (oral, dose-dependent) — Nausea, bloating, diarrhea, and abdominal discomfort are reported at higher doses (above 1000 mg/day for NMN, above 600 mg/day for NR). These are generally mild and resolve with dose reduction
• Flushing and skin warmth (oral, occasional) — Some users report mild flushing similar to niacin, particularly with higher-dose NMN. This is typically transient and not clinically significant
• IV-specific side effects (significant) — Chest pressure, nausea, cramping, anxiety, and headache during NAD+ infusions. Intensity correlates with infusion rate. Some patients report insomnia for 24-48 hours post-infusion
• Theoretical cancer concern — NAD+ fuels cellular energy metabolism indiscriminately. Rapidly dividing cancer cells may benefit from elevated NAD+ availability. Several preclinical studies have shown that NAD+ supplementation can accelerate tumor growth in mouse cancer models. No human study has demonstrated increased cancer risk, but the theoretical concern is biologically plausible and is the most serious potential risk of chronic NAD+ supplementation
• Methylation depletion — NAD+ synthesis and degradation involve methylation reactions. Chronic high-dose NAD+ precursor supplementation could theoretically deplete methyl donors (SAMe, folate, B12). Some clinicians recommend concurrent methylation support (TMG/betaine) with high-dose NMN or NR, though clinical evidence for this concern is limited
• Drug interactions — NAD+ metabolism intersects with several drug pathways. PARP inhibitors (used in oncology) and sirtuin-modulating drugs could theoretically interact with NAD+ supplementation. Patients on chemotherapy or PARP inhibitor therapy should discuss NAD+ supplementation with their oncologist

Delivery methods compared: oral, sublingual, IV, and patches

The evidence hierarchy is clear: oral NMN and NR have the most human data, followed distantly by IV NAD+. Everything else — nasal sprays, patches, suppositories, liposomal formulations — is marketed on theoretical arguments without published pharmacokinetic validation in humans. That does not mean they cannot work; it means you are paying a premium for unverified claims.

Legal and regulatory status (as of April 2026)

NAD+ and its precursors occupy a relatively favorable regulatory position compared to most compounds discussed in the peptide and longevity space. NR (nicotinamide riboside) has received GRAS status from the FDA and is sold as the dietary supplement Tru Niagen through normal retail channels with no legal restrictions.

NMN's regulatory path has been more turbulent. In late 2022, the FDA briefly challenged NMN's status as a dietary supplement, arguing that it was being investigated as a new drug (by Metro International Biotech, Sinclair's company) and therefore could not be sold as a supplement under the Federal Food, Drug, and Cosmetic Act. This created significant market uncertainty. As of 2026, NMN remains widely available as a dietary supplement in the US market, with the FDA's challenge not having resulted in a formal ban.

Critically, NAD+ and its precursors are not on the FDA's Category 2 bulk substances list that has restricted access to many peptides. This means they remain available through normal supplement channels, compounding pharmacies, and IV wellness clinics without the sourcing and legality concerns that affect compounds like BPC-157 or growth hormone secretagogues.

The central controversy: does raising NAD+ actually extend healthspan?

The NAD+ field in 2026 faces a credibility test. The mouse data is now more than a decade old and has been replicated across multiple laboratories. NMN and NR reliably rejuvenate aspects of aging in mice — this is not in serious dispute. The question that the next five years of research must answer is whether the same biology applies in humans.

The skeptical case is this: mice live two years. Humans live eighty. The metabolic rate differences, the scale of the NAD+ pool relative to body mass, the complexity of human aging biology, and the dozens of redundant repair and maintenance systems in human cells may mean that NAD+ supplementation in humans produces a biochemically measurable but clinically irrelevant effect. Raising blood NAD+ by 50% may simply mean you have 50% more NAD+ in your blood — full stop, no downstream functional improvement.

The optimistic case is equally coherent: NAD+ depletion is a conserved feature of mammalian aging, sirtuins are highly conserved from yeast to humans, and the early human trials showing cardiovascular and insulin-sensitizing benefits suggest the mouse-to-human translation is working, just at a smaller effect size that requires larger trials to detect reliably. The coming ALIVE-2 and similar large-scale studies should resolve this question.

The pragmatic position: if you are otherwise healthy, financially comfortable, and interested in longevity optimization, oral NMN or NR at moderate doses (250-500 mg daily) represents a low-risk experiment with plausible but unproven benefit. If you are looking for the single highest-impact intervention for metabolic health and longevity, the evidence overwhelmingly favors exercise, sleep optimization, and maintaining a healthy body weight — interventions with thousands of human studies behind them, not dozens.

Frequently asked questions

Bottom line

NAD+ is a genuinely important molecule. Its decline with age is well-documented, its role in critical cellular pathways is established beyond debate, and the preclinical data supporting restoration strategies is among the most compelling in longevity biology. The commercial NAD+ supplementation industry has built a billion-dollar market on these facts.

What the industry consistently undersells is the gap between biochemical mechanism and clinical outcome. Raising NAD+ levels in humans is easy — NMN and NR do it reliably. Proving that raised NAD+ levels produce meaningful improvements in human healthspan is the hard part, and it has not been accomplished. The trials completed so far show small, inconsistent benefits in specific endpoints. That is not failure — it is early-stage medicine doing what early-stage medicine does: generating signals that need larger, longer trials to confirm or refute.

For anyone serious about longevity, NAD+ supplementation belongs in the conversation. Oral NMN or NR at moderate doses (250-500 mg daily) from a reputable source reliably restores NAD+ levels toward youthful ranges, and the emerging human trial signals — improved vascular function, enhanced insulin sensitivity, better exercise capacity — are consistent with the robust preclinical data. Combined with the foundational longevity interventions (regular exercise, adequate sleep, healthy body composition), NAD+ restoration represents one of the more biologically grounded additions to a longevity protocol.

Keep reading

Peptides

SS-31 (Elamipretide): the mitochondrial-targeted peptide — 2026 evidence-based guide

Peptides

MOTS-C: the mitochondrial exercise-mimetic peptide — 2026 evidence-based guide

Peptides

Epitalon: the telomerase-activating longevity peptide — 2026 evidence-based guide